Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (841-850 of 962) with videos related to

Pageof 97
Sort By:
European Heart Journal|November 17, 2019
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysisPeter R Sinnaeve, Gregory G Schwartz, Daniel M Wojdyla, et al.
The New England Journal of Medicine|November 8, 2018
Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeGregory G Schwartz, P Gabriel Steg, Michael Szarek, et al.
Circulation. Cardiovascular Interventions|March 30, 2025
Effect of Red Blood Cell Transfusion Strategy on Clinical Outcomes Among Patients With Acute Myocardial Infarction Undergoing Revascularization: A Prespecified Analysis of the MINT TrialSunil V Rao, Maria Mori Brooks, Helen E A D'Agostino, et al.
Circulation. Cardiovascular Interventions|May 24, 2024
Three-Year Outcomes With Fractional Flow Reserve-Guided or Angiography-Guided Multivessel Percutaneous Coronary Intervention for Myocardial InfarctionEtienne Puymirat, Guillaume Cayla, Tabassome Simon, et al.
The American Journal of Cardiology|October 16, 2020
Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS)Hideyuki Kawashima, Mariusz Tomaniak, Masafumi Ono, et al.
The American Journal of Medicine|January 3, 2015
Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-upSami M A Alnasser, Wei Huang, Joel M Gore, et al.
The New England Journal of Medicine|November 17, 2020
Sotagliflozin in Patients with Diabetes and Chronic Kidney DiseaseDeepak L Bhatt, Michael Szarek, Bertram Pitt, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 21, 2019
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54Mikael Dellborg, Marc P Bonaca, Robert F Storey, et al.
Journal of the American College of Cardiology|May 9, 2020
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES TrialDeepak L Bhatt, Andrew H Briggs, Shelby D Reed, et al.
European Journal of Heart Failure|November 7, 2023
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trialMorten Schou, Brian Claggett, Zi Michael Miao, et al.
Pageof 97

Showing results (841-850 of 962) with videos related to

Sort By:
Pageof 97
European Heart Journal|November 17, 2019
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysisPeter R Sinnaeve, Gregory G Schwartz, Daniel M Wojdyla, et al.
The New England Journal of Medicine|November 8, 2018
Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeGregory G Schwartz, P Gabriel Steg, Michael Szarek, et al.
Circulation. Cardiovascular Interventions|March 30, 2025
Effect of Red Blood Cell Transfusion Strategy on Clinical Outcomes Among Patients With Acute Myocardial Infarction Undergoing Revascularization: A Prespecified Analysis of the MINT TrialSunil V Rao, Maria Mori Brooks, Helen E A D'Agostino, et al.
Circulation. Cardiovascular Interventions|May 24, 2024
Three-Year Outcomes With Fractional Flow Reserve-Guided or Angiography-Guided Multivessel Percutaneous Coronary Intervention for Myocardial InfarctionEtienne Puymirat, Guillaume Cayla, Tabassome Simon, et al.
The American Journal of Cardiology|October 16, 2020
Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS)Hideyuki Kawashima, Mariusz Tomaniak, Masafumi Ono, et al.
The American Journal of Medicine|January 3, 2015
Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-upSami M A Alnasser, Wei Huang, Joel M Gore, et al.
The New England Journal of Medicine|November 17, 2020
Sotagliflozin in Patients with Diabetes and Chronic Kidney DiseaseDeepak L Bhatt, Michael Szarek, Bertram Pitt, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 21, 2019
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54Mikael Dellborg, Marc P Bonaca, Robert F Storey, et al.
Journal of the American College of Cardiology|May 9, 2020
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES TrialDeepak L Bhatt, Andrew H Briggs, Shelby D Reed, et al.
European Journal of Heart Failure|November 7, 2023
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trialMorten Schou, Brian Claggett, Zi Michael Miao, et al.
Pageof 97